Literature DB >> 22362009

Features of Japanese patients with myelodysplastic syndrome in an aging population of Sado Island.

Kumiko Yagisawa1, Kiyoshi Okazuka, Ken Toba, Masaru Urushiyama, Takashi Kuroha, Noriko Izumi, Yasuhiko Sibasaki, Masutaka Higashimura, Toshio Yano, Akihito Momoi, Akira Hattori, Ken Momotsu, Yoshifusa Aizawa.   

Abstract

Myelodysplastic syndrome (MDS) is relatively common in the elderly, and aging of populations is progressing in developed nations, notably so in Japan. The major age group in Japan and Sado Island are distributed between 30 and 60 and between 50 and 80, respectively. The aim of this study was to analyze the features of MDS in the population of Sado Island to anticipate the characteristics of the disease in the near future. One-hundred and fifty-three patients (71 male, 82 female, 19-94 years old, median 73 years old) with de novo MDS between 1985 and 2005 were retrospectively evaluated. All patients were reclassified according to WHO-2001 criteria. The predictive power of the international prognostic scoring system and the WHO classification-based prognostic scoring system were evaluated. The major causes of death were leukemic transformation (38%) in refractory anemia with an excess of blasts and infection (48%) for total MDS. Age was another independent prognostic factor. Elderly patients exhibited a significantly poorer prognosis mainly due to infections such as pneumonia. Although novel remedies for MDS and hyperferremia have recently been developed, prevention of infection remains important in MDS, particularly for older patients.

Entities:  

Mesh:

Year:  2012        PMID: 22362009     DOI: 10.1007/s12185-012-1031-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  33 in total

1.  Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

Authors:  David Bowen; Dominic Culligan; Simon Jowitt; Stephen Kelsey; Ghulam Mufti; David Oscier; Jane Parker
Journal:  Br J Haematol       Date:  2003-01       Impact factor: 6.998

2.  Distinct haematological disorder with deletion of long arm of no. 5 chromosome.

Authors:  H Van den Berghe; J J Cassiman; G David; J P Fryns; J L Michaux; G Sokal
Journal:  Nature       Date:  1974-10-04       Impact factor: 49.962

3.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

Authors:  Alan List; Gordon Dewald; John Bennett; Aristotle Giagounidis; Azra Raza; Eric Feldman; Bayard Powell; Peter Greenberg; Deborah Thomas; Richard Stone; Craig Reeder; Kenton Wride; John Patin; Michele Schmidt; Jerome Zeldis; Robert Knight
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome.

Authors:  Y Kita-Sasai; S Horiike; S Misawa; H Kaneko; M Kobayashi; M Nakao; H Nakagawa; H Fujii; M Taniwaki
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

5.  Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).

Authors:  Christian Rose; Sabine Brechignac; Dominique Vassilief; Laurent Pascal; Aspasia Stamatoullas; Agnes Guerci; Dalila Larbaa; François Dreyfus; Odile Beyne-Rauzy; Marie Pierre Chaury; Lydie Roy; Stephane Cheze; Pierre Morel; Pierre Fenaux
Journal:  Leuk Res       Date:  2010-02-02       Impact factor: 3.156

6.  Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare.

Authors:  S Oguma; Y Yoshida; H Uchino; T Maekawa; T Nomura; H Mizoguchi
Journal:  Leuk Res       Date:  1995-03       Impact factor: 3.156

7.  Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes.

Authors:  T Nösslinger; H Tüchler; U Germing; W R Sperr; O Krieger; D Haase; M Lübbert; R Stauder; A Giagounidis; P Valent; M Pfeilstöcker
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

8.  Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Authors:  Azra Raza; James A Reeves; Eric J Feldman; Gordon W Dewald; John M Bennett; H Joachim Deeg; Luke Dreisbach; Charles A Schiffer; Richard M Stone; Peter L Greenberg; Peter T Curtin; Virginia M Klimek; Jamile M Shammo; Deborah Thomas; Robert D Knight; Michele Schmidt; Kenton Wride; Jerome B Zeldis; Alan F List
Journal:  Blood       Date:  2007-09-24       Impact factor: 22.113

9.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

10.  Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.

Authors:  C Aul; N Gattermann; W Schneider
Journal:  Br J Haematol       Date:  1992-10       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.